



Vista Pharmaceuticals Ltd

CIN : L24239TG1991PLC012264
Plot No. 104, Ravindra Co Operative Society, Guttala Begumpet,
Kakateeya Hills, Hyderabad - 500 081. Telangana, INDIA. Tel : 040 - 23741585
E-mail : admin.hyd@vistapharmaceuticals.com @www.vistapharmaceuticals.com

To,
BSE Limited,
P.J. Towers, Dalal Street,
Mumbai - 400001

Date: 13.08.2024

Dear Sir/Madam,

Sub: Outcome of board meeting under regulations 30 read with 33 (3) of SEBI (Listing Obligations and Disclosure requirements) regulations, 2015

Unit: Vista Pharmaceuticals Limited (BE Scrip Code:524711)

With reference to the subject cited, this is to inform the Exchange that at the Board meeting of M/s. Vista Pharmaceuticals Limited held on Tuesday, the 13th day of August, 2024, at 03.00 P.M. at the registered office of the Company, the Company the following were duly considered and approved by the Board:

1. Un-Audited Financial results for the quarter ended 30.06.2024
2. Limited Review Report for the quarter ended 30.06.2024
3. Recommended for the approval of the members, reappointment of Mr. Mallem Hanumantha Rao (DIN: 00129311) who retires by rotation and being eligible, offers himself for re appointment.
4. Recommended for the approval of the members, reappointment of Mr. Stanley Prabhakar Reddy (DIN: 07614532) who retires by rotation and being eligible, offers himself for re appointment
5. Approval of the AGM Notice and Director's Report for the year ended March 31, 2024 along with Annexures thereto.
6. Convening of 33rd Annual General Meeting (AGM) of the Company on Monday, the 30th Day of September, 2024, at 10:30 AM through Video Conferencing ("VC") / Other Audio-Visual Means ("OAVM"), the venue of the AGM shall be deemed to be the Registered Office of the Company
6. The Register of Members and Share Transfer Books of the company will remain closed from 24.09.2024 to 30.09.2024 (both days inclusive) pursuant to regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.



Vista Pharmaceuticals Ltd

CIN : L24239TG1991PLC012264
Plot No. 104, Ravindra Co Operative Society, Guttala Begumpet,
Kakateeya Hills, Hyderabad - 500 081. Telangana, INDIA. Tel : 040 - 23741585
E-mail : admin.hyd@vistapharmaceuticals.com @www.vistapharmaceuticals.com

7. Appointment of Mr. Sarveswar Reddy, Practicing Company Secretary as scrutinizer for evaluating the voting process for 33rd Annual General Meeting of the Company.

The meeting of the Board of Directors commenced at 3.00 P.M.(IST) and concluded at 04.50 P.M. (IST)

This is for the information and records of the Exchange, please.

Thanking you.

Yours faithfully,
For Vista Pharmaceuticals Limited



Dhananjaya Alli
Executive Director
(DIN: 00610909)



Vista Pharmaceuticals Ltd

CIN : L24239TG1991PLC012264
 Plot No. 104, Ravindra Co Operative Society, Guttala Begumpet,
 Kakateeya Hills, Hyderabad - 500 081. Telangana, INDIA. Tel : 040 - 23741585
 E-mail : admin.hyd@vistapharmaceuticals.com @www.vistapharmaceuticals.com

Statement of Un-Audited financial results for the Quarter ended 30.06.2024

(Rs. in Lakhs)

S.No	Particulars	Quarter ended			Year Ended
		June 30,2024	March 31,2024	June 30,2023	March 31,2024
		Un Audited	Audited	Un Audited	Audited
1	Income				
	a. Revenue from operations	179.50	313.25	198.10	1028.78
	b. Other income	7.11	9.76	13.21	33.34
2	Total Income (a+b)	186.61	323.01	211.31	1062.12
3	Expenses				
	a) Cost of Material Consumed	160.27	149.35	206.37	888.25
	b) Change in Inventories	-	0.77	(9.46)	0.77
	c) Employee benefits expense	44.97	47.73	41.73	179.47
	d) Finance costs	28.25	27.79	32.67	121.98
	e) Depreciation and amortization expense	18.32	18.05	17.34	71.97
	f) Other expenses	51.93	89.13	51.56	291.75
	g) Prior Period Expenses	-	0.02	-	25.67
	Total Expenses	303.74	332.85	340.21	1,579.86
4	Profit before tax (2-3)	(117.13)	(9.84)	(128.91)	(517.74)
5	Tax expense				
	(1) Current tax	-	0.00	0.00	0.00
	(2) Deferred tax	(31.43)	(18.91)	(33.45)	(66.54)
	(3) Previous year Income tax adjustment	-	-	-	-
6	Net Profit for the Period (4-5)	(85.70)	9.07	(95.46)	(451.20)
7	Other comprehensive income (OCI)				
	Items that will not be reclassified Subsequently to profit or loss	0.41	(0.28)	0.12	0.29
	Tax on items that may not be reclassified to profit or loss	-	-	-	-
	Items that will be reclassified to profit or loss:	-	-	-	-
	Total Other Comprehensive income	0.41	(0.28)	0.12	0.29
8	Total Comprehensive income (6+7)	-85.29	8.79	-95.34	-450.91
9	Paid- up equity share capital(Face Value of Rs.2/- each)	1231.04	943.30	855.34	943.30
10	Other Equity				
11	Earnings per equity share				
	(Face value of Rs.10/- each)				
	(1) Basic	-0.15	0.02	-0.23	0.03
	(2) Diluted	-0.15	0.01	-0.15	0.07





Vista Pharmaceuticals Ltd

CIN : L24239TG1991PLC012264

Plot No. 104, Ravindra Co Operative Society, Guttala Begumpet,

Kakateeya Hills, Hyderabad - 500 081. Telangana, INDIA. Tel : 040 - 23741585

E-mail : admin.hyd@vistapharmaceuticals.com www.vistapharmaceuticals.com

Notes:

1. The financial results of the company have been prepared in accordance with Indian Accounting Standards (Ind AS) notified under the companies (Indian Accounting standards) Rules, 2015 as amended by the companies (Indian Accounting standards) (Amendment) rules, 2016.
2. The above Financial results recommended by the Audit Committee are considered and approved by the Board of Directors at their meeting held on 13th August , 2024
3. The Statutory Auditors of the Company have carried out "Limited Review" of the above unaudited financial results and their Report has been placed before the Board at the said Meeting as required under Regulation 33 of SEBI (LODR) Regulations, 2015.
4. Total Revenue for the current quarter is Rs.179.50 Lakhs compared to Rs.198.10 Lakhs for the corresponding quarter of the previous year.
5. The Loss before tax for the current quarter is Rs. 117.93 Lakhs compared to Profit Before tax of Rs. 128.91 Lakhs for the corresponding quarter of the previous year.
6. The Profit/(Loss) After tax for the current quarter is Rs.(85.70) Lakhs compared to Rs. (95.46) Lakhs for the corresponding quarter of the previous year.
7. The Entire operations of the Company relate to only one segment i.e Manufacturing of Pharmaceutical Products., Hence, segmental reporting as per IND AS-108 is not made.
8. The results for the quarter ended 30th June 2024 are also available on the bomabay stock exchange website, the National Stock exchange website and on the Company's website.

Place:Hyderabad

Date:13.08.2024



For Vista Pharmaceuticals Limited

Dhananjaya Alli
Whole time Director
(DIN: 00610909)



A.M REDDY & D.R REDDY Chartered Accountants

Independent Auditor's Review Report on unaudited Quarterly Financial results of VISTA PHARMACEUTICALS LIMITED Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To,
The Board of Directors,
Vista Pharmaceuticals Limited.

1. We have reviewed the accompanying statement of unaudited financial results of Vista Pharmaceuticals Limited ("the Company") for the quarter ended June 30, 2024 and year to date results for the period April 01, 2024 to June 30, 2024 ("the Statement ") attached herewith, being submitted by the company Pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Regulation")
2. This Statement, which is the responsibility of the company's Management and approved by the Board of Directors, has been Prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 "Interim Financial Reporting", prescribed under Section 133 of the companies act, 2013 read with relevant rules issued there under and other recognised accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We Conducted our review of the statement in accordance with the Standard of Review engagement (SRE) 2410, "Review of Interim Financial Information Performed by the independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether financial results are free of material misstatements. A review Consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to



obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit Opinion.

4. Based on our review conducted and Procedures performed as stated in Paragraph 3 as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited Financial results prepared in accordance with the recognition and measurement principles laid down in IND AS 34, Prescribed under Section 133 of the Companies act, 2013 read with relevant rules issued thereunder and other recognized accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the regulation including the manner in which it is to be disclosed, or that it contains any material misstatement.

For A.M REDDY & D.R REDDY

Chartered Accountants



D.Rama Krishna Reddy

Partner

Membership No. 209211

UDIN: 24209211BKHHRZ8350

Place: Hyderabad

Date: August 13, 2024

